BioCentury
ARTICLE | Strategy

Transforming BeiGene

Why BeiGene changed its mind about selling its own drugs in China

July 14, 2017 11:31 PM UTC

BeiGene Ltd.’s deal with Celgene Corp. for BGB-A317 does more than provide the Chinese biotech with a partner that can compete in the PD-1 space from a development and commercial perspective. It also marks a turning point that will now see BeiGene selling cancer drugs in China, and possibly in-licensing assets for its pipeline.

On July 5, the partners announced BeiGene granted Celgene exclusive rights to BGB-A317 for solid tumor indications in ex-Asia markets, plus Japan. BeiGene retains rights for solid tumors in the rest of Asia, along with worldwide rights for hematological malignancies. ...